These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34703332)

  • 41. Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis.
    Fleischmann R; Liu J; Zhu J; Segurado OG; Furst DE
    Arthritis Care Res (Hoboken); 2022 Sep; 74(9):1477-1483. PubMed ID: 33644992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Narrative Review of Acthar Gel for the Treatment of Myositis.
    Chandra T; Aggarwal R
    Rheumatol Ther; 2023 Jun; 10(3):523-537. PubMed ID: 36966453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
    Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States.
    Nelson WW; Lima AF; Kranyak J; Opong-Owusu B; Ciepielewska G; Gallagher JR; Heap K; Carroll S
    J Ocul Pharmacol Ther; 2019 Apr; 35(3):182-188. PubMed ID: 30676837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis.
    Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio MP; Wan GJ
    J Health Econ Outcomes Res; 2022; 9(1):90-100. PubMed ID: 35529249
    [No Abstract]   [Full Text] [Related]  

  • 46. Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China.
    Shi Y; Xie Y; Zhang G; Feng Y
    Intern Emerg Med; 2022 Apr; 17(3):703-714. PubMed ID: 34559374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acthar® Gel (repository corticotropin injection) dose-response relationships in an animal model of epileptic spasms.
    Le JT; Frost JD; Swann JW
    Epilepsy Behav; 2021 Mar; 116():107786. PubMed ID: 33548914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
    Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
    Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
    Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort.
    Tillett W; Birt J; Cavanaugh C; Jung Y; Vadhariya A; Ross S; Paulus J; Lubrano E
    Front Med (Lausanne); 2023; 10():1184028. PubMed ID: 37415769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome.
    Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
    Curr Med Res Opin; 2021 Mar; 37(3):431-441. PubMed ID: 33411573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repository Corticotropin Injection (Acthar
    Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
    Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Databases of patients with early rheumatoid arthritis in the USA.
    Sokka T; Willoughby J; Yazici Y; Pincus T
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S146-53. PubMed ID: 14969067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA.
    Bell CF; Huang SP; Yu LH; DerSarkissian M; Germain G; Concoff AL; Averell CM; Rubin B; Gu YM; Duh MS; Wallace DJ
    Rheumatol Ther; 2023 Feb; 10(1):261-274. PubMed ID: 36471198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Follow-up results of myositis patients treated with H. P. Acthar gel.
    Saygin D; Oddis CV; Marder G; Moghadam-Kia S; Nandkumar P; Neiman N; Dzanko S; Koontz D; Aggarwal R
    Rheumatology (Oxford); 2020 Oct; 59(10):2976-2981. PubMed ID: 32160301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.
    Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
    Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry.
    England BR; Yun H; Chen L; Vanderbleek J; Michaud K; Mikuls TR; Curtis JR
    Arthritis Care Res (Hoboken); 2023 Feb; 75(2):231-239. PubMed ID: 34338449
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.